Concomitant epidermal growth factor receptor mutation/c-ros oncogene 1 rearrangement in non-small cell lung cancer: A case report  

作　　者：Gui-Qin Peng Hai-Chi Song Wan-Yi Chen 

机构地区：[1]Department of Pharmacy,Chongqing University Cancer Hospital,Chongqing 400030,China

出　　处：《World Journal of Clinical Oncology》2024年第7期945-952,共8页世界临床肿瘤学杂志（英文版）

基　　金：Supported by Wu Jieping Medical Foundation,No.320.6750.2022-20-25;and Chongqing Health Commission,No.[2020]68.

摘　　要：BACKGROUND Epidermal growth factor receptor(EGFR)mutation and c-ros oncogene 1(ROS1)rearrangement are key genetic alterations and predictive tumor markers for non-small cell lung cancer(NSCLC)and are typically considered to be mutually exc-lusive.EGFR/ROS1 co-mutation is a rare event,and the standard treatment appr-oach for such cases is still equivocal.CASE SUMMARY Herein,we report the case of a 64-year-old woman diagnosed with lung adenocar-cinoma,with concomitant EGFR L858R mutation and ROS1 rearrangement.The patient received two cycles of chemotherapy after surgery,but the disease prog-ressed.Following 1-month treatment with gefitinib,the disease progressed again.However,after switching to crizotinib,the lesion became stable.Currently,crizotinib has been administered for over 53 months with a remarkable treatment effect.CONCLUSION The efficacy of EGFR tyrosine kinase inhibitors and crizotinib was vastly different in this NSCLC patient with EGFR/ROS1 co-mutation.This report will aid future treatment of such patients.

关 键 词：Non-small cell lung cancer Epidermal growth factor receptor C-ros oncogene 1 Co-mutation Treatment strategies Case report 

分 类 号：R73[医药卫生—肿瘤]